Home » Stocks » Keros Therapeutics

Keros Therapeutics, Inc. (KROS)

Stock Price: $35.80 USD -0.66 (-1.81%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 721.32M
Revenue (ttm) 7.50M
Net Income (ttm) n/a
Shares Out 20.15M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $35.80
Previous Close $36.46
Change ($) -0.66
Change (%) -1.81%
Day's Open 36.81
Day's Range 34.80 - 37.78
Day's Volume 75,491
52-Week Range 19.10 - 42.26

More Stats

Market Cap 721.32M
Enterprise Value 667.88M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 20.15M
Float 8.85M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 811,117
Short Ratio 13.05
Short % of Float 11.33%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 96.18
PB Ratio 99.73
Revenue 7.50M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 53.45M
Net Cash / Share 2.65
Gross Margin -98.39%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.41%
ROE -186.16%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(21.51% upside)
Current: 35.80
Target: 43.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth0%-
Gross Profit10.0010.00
Operating Income-10.56-1.69
Net Income-14.14-2.35
Shares Outstanding2.332.17
Earnings Per Share-6.08-1.08
Operating Cash Flow-16.007.04
Capital Expenditures-0.27-0.22
Free Cash Flow-16.276.83
Cash & Equivalents7.1423.39
Total Debt1.280.79
Net Cash / Debt5.8622.60
Book Value-19.45-7.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Keros Therapeutics, Inc.
Country United States
Employees 26
CEO Jasbir S. Seehra

Stock Information

Ticker Symbol KROS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KROS


Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.